New PHM global coordinator: “Palestine is a symbol of resistance for a new world”
Pharmacist Aziz Rhali is to lead PHM with a vision of Palestine as global resistance symbol, advancing the health movement’s strategic vision.
Indonesian health coalition demands return of protections against patent evergreening
The Coalition for Patient Rights Advocacy for Access to Medicines is pursuing a judicial review of the 2024 Indonesian Patent Law, calling for the return of crucial protections against patent evergreening.
US–UK pharma deal sacrifices patients for profit
Access to medicines activists warn the new US–UK pharma deal will have catastrophic impacts, including thousands of preventable deaths each year.
Europe’s Palestine solidarity movement strengthens call to boycott Israeli pharmaceutical company Teva
Pressure is mounting on local governments and public pharmacies to replace Teva products with alternatives not complicit in Israel’s occupation and genocide.
Mexico raises the flag for health sovereignty
Mexico launches a national plan to expand domestic drug production and move toward a free, universal, and public healthcare system.
Reclaiming drug discovery: why we need public pharma
Big Pharma thrives on profiting from publicly funded innovation: but Public Pharma can take back control and put health over profit.
Against the normalization of limited access to CAR-T cell therapies
European hospitals and research centers have a chance to make CAR-T cancer therapies more accessible — the question is whether they’ll take it
Is Big Pharma’s pollution deregulation campaign fueling the next pandemic?
Big Pharma keeps pushing for weaker pollution standards despite proven risks to human and environmental health
Public Pharma: still a missing debate in mainstream academia
Despite drug shortages and soaring prices, mainstream academia continues to ignore Public Pharma as a solution
WHO Executive Board to discuss substandard medical products: what is it all about?
The WHO Executive Board will discuss global health priorities this week, including substandard and falsified medical products, with key implications for public pharmaceutical initiatives
Can Serbia “cure” its public pharmacies?
Pharmacy services in Serbia have become entirely profit-driven, with the needs of the population pushed aside






